| Edition |
1st ed. |
| Description |
1 online resource (xv, 473 pages, 27 unnumbered pages of plates) : illustrations (some color) |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
| Bibliography |
Includes bibliographical references and index. |
| Contents |
Modern cancer drug discovery : integrating targets, technologies and treatments / Paul Workman and Ian Collins -- Preclinical pharmacology and in vivo models / Lloyd Kelland -- Clinical trial designs for more rapid proof-of-principle and approval / Mitesh J. Borad and Daniel D. Van Hoff -- Structural biology and anticancer drug design / Dominic Tisi [and others] -- Natural product chemistry and anticancer drug discovery / Donna M. Huryn and Peter Wipf -- Pharmacokinetics and ADME optimization in drug discovery / Chad L. Stoner, Matthew D. Troutman and Caroline E. Laverty -- Temozolomide : from cytotoxic to molecularly-targeted agent / Malcolm F.G. Stevens -- Camptothecins for drug design, cancer cell death and gene targeting / Jérôme Kluza [and others] -- Targeting thymidylate synthase by antifolate drugs for the treatment of cancer / Ann L. Jackman, Martin Forster and Matthew Ng -- Targeting inactive kinases : structure as a foundation for cancer drug discovery / David J. Hosfield and Clifford D. Mol -- Cell cycle inhibitors in cancer : current status and future directions / Peter M. Fischer -- Inhibition of DNA repair as a therapeutic target / Nicola J. Curtin and Thomas Helleday -- HSP90 inhibitors : targeting the cancer chaperone for combinatorial blockade of oncogenic pathways / Swee Y. Sharp, Keith Jones and Paul Workman -- Heat shock protein-90 directed therapeutics and target validation / Edward A. Sausville -- Inhibitors of tumor angiogenesis / Adrian L. Harris and Daniele G. Generali -- The biology and oncology of RAF-ERK signaling / Victoria Emuss and Richard Marais -- Cancer drug resistance / V. Karavasilis [and others] -- Failure modes in anticancer drug discovery and development / Homer L. Pearce, Kerry L. Blanchard and Christopher A. Slapak. |
| Note |
Print version record. |
| Summary |
The ultimate source of information on the design of new anticancer agents, emphasising small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumours. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry, and clinicians taking oncology options. * Covers both currently available drugs as well as those under development * Provides a clinical perspective on trials of new anticancer agents * Presents drug discovery examples through the use of case histories. |
| Subject |
Antineoplastic agents -- Development.
|
|
Antineoplastic agents -- Design.
|
|
Cancer -- Chemotherapy.
|
|
Antimitotic agents.
|
|
Antineoplastic agents.
|
|
Drugs -- Design.
|
|
Antineoplastic Agents |
|
Antimitotic Agents |
|
Drug Design |
|
Neoplasms -- drug therapy |
|
Cancer -- Chimiothérapie.
|
|
Anticancéreux.
|
|
Médicaments -- Conception.
|
|
MEDICAL -- Oncology.
|
|
HEALTH & FITNESS -- Diseases -- Cancer.
|
|
Drugs -- Design
|
|
Antineoplastic agents
|
|
Antimitotic agents
|
|
Antineoplastic agents -- Design
|
|
Antineoplastic agents -- Development
|
|
Cancer -- Chemotherapy
|
| Added Author |
Neidle, Stephen. Editor.
|
| Other Form: |
Print version: Cancer drug design and discovery. 1st ed. New York : Academic Press, ©2008 9780123694485 0123694485 (OCoLC)154760280 |
| ISBN |
9780080554952 (electronic bk.) |
|
0080554954 (electronic bk.) |
|
9780123694485 |
|
0123694485 |
| Standard No. |
AU@ 000050896175 |
|
AU@ 000051555928 |
|
DEBBG BV043158102 |
|
DEBSZ 422087041 |
|
GBVCP 802759815 |
|
UKMGB 017596573 |
|
